ArticleJournal of the American Society of Nephrology : JASN2025

Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.

Richard Lafayette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.